May 17, 2017 – Following up on an earlier Drug Safety Communication from May 2016 and based on new data from two large clinical trials, the American Food & Drug Administration (FDA) has concluded that the type 2 diabetes medicines …

Risk of leg and foot amputations under Canagliflozin (Invokana, Invokamet) Read more »

Lønnberg AS, Skov L, Skytthe A, Kyvik KO, Pedersen OB, Thomsen SF JAMA Dermatol 2016 Apr; PMID: 27120802 Abstract Importance: Psoriasis has been shown to be associated with overweight and type 2 diabetes mellitus. The genetic association is unclear. Objective: …

Association of Psoriasis With the Risk for Type 2 Diabetes Mellitus and Obesity Read more »

September 18, 2014 – We learn today from the U.S. Food and Drug Administration (FDA) of the approval of  Trulicity (dulaglutide), a once-weekly subcutaneous injection to improve glycemic control (blood sugar levels), along with diet and exercise, in adults with …

Dulaglutide [Trulicity], a glucagon-like peptide-1 (GLP-1) receptor agonist, approved for the treatment of type 2 diabetes Read more »

August 1, 2014 – The U.S. Food and Drug Administration today approved Jardiance (empagliflozin) tablets as an addition to diet and exercise to improve glycemic control in adults with type 2 diabetes. Type 2 diabetes affects approximately 26 million people …

FDA approves Empagliflozin [Jardiance], a SGLT2 inhibitor, to treat type 2 diabetes Read more »